Total Payments
$6,012
2024 Payments
$663.31
Companies
23
Transactions
327
Medicare Patients
2,832
Medicare Billing
$446,061
Payment Breakdown by Category
Food & Beverage$5,481 (91.2%)
Education$531.68 (8.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,481 | 319 | 91.2% |
| Education | $531.68 | 8 | 8.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $1,054 | 59 | $0 (2024) |
| Janssen Biotech, Inc. | $992.65 | 67 | $0 (2023) |
| ABBVIE INC. | $802.11 | 35 | $0 (2024) |
| Gilead Sciences, Inc. | $530.11 | 41 | $0 (2024) |
| Allergan, Inc. | $497.21 | 36 | $0 (2020) |
| Insmed, Inc. | $485.73 | 19 | $0 (2024) |
| Janssen Products, LP | $413.96 | 5 | $0 (2022) |
| Merck Sharp & Dohme LLC | $333.92 | 21 | $0 (2024) |
| The Medicines Company | $151.90 | 4 | $0 (2017) |
| Shionogi Inc | $128.63 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $663.31 | 28 | ABBVIE INC. ($272.02) |
| 2023 | $899.87 | 46 | AbbVie Inc. ($294.02) |
| 2022 | $993.61 | 44 | ViiV Healthcare Company ($208.38) |
| 2021 | $497.00 | 30 | ViiV Healthcare Company ($120.22) |
| 2020 | $497.57 | 25 | Allergan, Inc. ($137.10) |
| 2019 | $710.65 | 52 | Allergan Inc. ($145.80) |
| 2018 | $704.73 | 44 | ViiV Healthcare Company ($140.61) |
| 2017 | $1,045 | 58 | Janssen Biotech, Inc. ($299.42) |
All Payment Transactions
327 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: HIV | ||||||
| 12/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: HIV | ||||||
| 12/05/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.56 | General |
| Category: HIV | ||||||
| 11/25/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.85 | General |
| 10/28/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/15/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: Respiratory | ||||||
| 07/17/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Respiratory | ||||||
| 06/26/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/15/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $30.68 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/14/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Respiratory | ||||||
| 04/30/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/05/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/20/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/18/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.06 | General |
| Category: Respiratory | ||||||
| 03/01/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: ANTIBIOTIC | ||||||
| 02/28/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/23/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/13/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: GI | ||||||
| 02/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: ANTIBIOTIC | ||||||
| 01/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: HIV | ||||||
| 01/23/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/22/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 635 | 1,078 | $238,783 | $95,254 |
| 2022 | 8 | 721 | 1,171 | $253,290 | $99,898 |
| 2021 | 7 | 720 | 1,216 | $248,456 | $105,057 |
| 2020 | 6 | 756 | 1,548 | $244,825 | $145,851 |
Total Patients
2,832
Total Services
5,013
Medicare Billing
$446,061
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 244 | 588 | $100,615 | $40,560 | 40.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 273 | 287 | $81,510 | $32,531 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 107 | $29,078 | $11,016 | 37.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 71 | $18,242 | $7,368 | 40.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $9,338 | $3,779 | 40.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 281 | 630 | $97,569 | $39,029 | 40.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 286 | 299 | $88,845 | $35,043 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 111 | $30,614 | $11,303 | 36.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 66 | $14,639 | $5,819 | 39.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $8,636 | $3,486 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $4,803 | $1,924 | 40.1% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $4,339 | $1,743 | 40.2% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2022 | 15 | 17 | $3,844 | $1,551 | 40.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 264 | 674 | $95,262 | $42,419 | 44.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 288 | 309 | $91,581 | $36,719 | 40.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 76 | $21,359 | $8,416 | 39.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 76 | $15,153 | $6,876 | 45.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 33 | 33 | $13,000 | $5,715 | 44.0% |
| 99219 | Hospital observation care, typically 50 minutes | Facility | 2021 | 34 | 34 | $9,922 | $4,029 | 40.6% |
| 99225 | Subsequent observation care, typically 25 minutes per day | Facility | 2021 | 13 | 14 | $2,179 | $883.26 | 40.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 226 | 657 | $65,700 | $42,125 | 64.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 127 | 445 | $60,075 | $41,300 | 68.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 155 | 161 | $48,300 | $29,215 | 60.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 189 | 204 | $56,100 | $25,318 | 45.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 56 | $8,400 | $4,884 | 58.1% |
About Dr. Gilberto Rodriguez, M.D
Dr. Gilberto Rodriguez, M.D is a Infectious Disease healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1205833597.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gilberto Rodriguez, M.D has received a total of $6,012 in payments from pharmaceutical and medical device companies, with $663.31 received in 2024. These payments were reported across 327 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($5,481).
As a Medicare-enrolled provider, Rodriguez has provided services to 2,832 Medicare beneficiaries, totaling 5,013 services with total Medicare billing of $446,061. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Miami, FL
- Active Since 07/01/2005
- Last Updated 10/04/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1205833597
Products in Payments
- PREZCOBIX (Drug) $770.11
- DALVANCE (Drug) $717.24
- SYMTUZA (Drug) $551.48
- AVYCAZ (Drug) $539.91
- Arikayce (Drug) $485.73
- DOVATO (Drug) $481.08
- APRETUDE (Biological) $196.12
- Fetroja (Drug) $128.63
- TRIUMEQ (Drug) $124.34
- PIFELTRO (Drug) $117.53
- VABOMERE (Drug) $114.29
- JULUCA (Drug) $100.38
- CABENUVA (Biological) $89.95
- Symtuza (Drug) $85.02
- DIFICID (Drug) $80.10
- NUZYRA (Drug) $79.81
- Cresemba (Drug) $68.40
- RUKOBIA (Drug) $62.02
- ISENTRESS (Drug) $55.45
- INFLECTRA (Biological) $46.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Miami
Douglas Brust, M.d, M.D
Infectious Disease — Payments: $450,213
Infectious Disease $450,213
Ricardo Fonseca Franco
Infectious Disease — Payments: $135,298
Infectious Disease $135,298
Hector Bolivar, Md, MD
Infectious Disease — Payments: $105,997
Infectious Disease $105,997
Jorge Murillo, Md, MD
Infectious Disease — Payments: $85,760
Infectious Disease $85,760
Dushyantha Jayaweera, Md, MD
Infectious Disease — Payments: $79,219
Infectious Disease $79,219
Dr. Lilian Abbo, Md, MD
Infectious Disease — Payments: $69,205
Infectious Disease $69,205